Replies to post #95 on StatSure Diagnostic Systems (SSUR)

[BonelessCat]

Improving Risk/Reward Ratio and Growth Outlook

[I especially like this part of the report. Thanks for posting that, nanopatent! --Doc FG]

Scimitar maintains a “BUY” ranking on SSUR.OB and has upgraded the
modeled valuation to $1.66 from $1.25 based on the impact of receipt of the
CLIA Waiver. The revenue impact of this “waiver” affects the risk/reward
scenario due primarily to SSUR.OB’s value drivers: a virtual operating mode
(manufacturing and marketing are outsourced), modest executive infrastructure,
the financial (margin) model (reflected by the terms of the “three-way deal); the
results of which provides for a high percentage of revenues to drop to the
bottom line. These value-drivers are transparent, simple and strong
determinants of SSUR.OB’s business and operating model.

http://www.scimitarequity.com/research/SSUR.OB_Mid-Quarter_Review.pdf